Clinical trials: Post-Polycythemia Vera MF (Post-PV-MF)
Myelofibrosis, Primary Myelofibrosis
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551066
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 15 more
- Volunteers
- 252 people
- Sponsor
- Incyte Corporation
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 (LCL161) works in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential…
- Conditions
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
- Trial name
- NCT02098161
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF)
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543)…
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
- Trial name
- NCT03136185
- Testing
- Bomedemstat
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 90 people
- Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF.
- Conditions
- Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF
- Trial name
- NCT01392443
- Testing
- Ruxolitinib
- Where
- 26 sites in China, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Myeloproliferative Disorders
Study of SB939 in Subjects With Myelofibrosis
The goal of this clinical research study is to learn if SB939 can help to control myelofibrosis. The safety of this drug will also be studied.
- Trial name
- NCT01200498
- Testing
- SB939
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Myelofibrosis, Thrombocytosis
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the…
- Conditions
- Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT01787552
- Testing
- LDE225, INC424
- Where
- 18 sites in Australia, Belgium and 9 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
This is a Phase IB, open-label, dose-finding study of the JAK 1 and 2 inhibitor ruxolitinib in patients with myelofibrosis (MF).
- Trial name
- NCT01317875
- Testing
- Ruxolitinib
- Where
- 18 sites in United States, Austria and 6 more
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
MPN (Myeloproliferative Neoplasms)
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10^9/L to 100 x 10^9/L.
- Trial name
- NCT01348490
- Testing
- Ruxolitinib
- Where
- 38 sites in United States
- Volunteers
- 66 people
- Sponsor
- Incyte Corporation
Myelofibrosis, Primary Myelofibrosis
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi).
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- MANIFEST-2 (NCT04603495)
- Testing
- Pelabresib, Ruxolitinib
- Where
- 156 sites in United States, Australia and 20 more
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- Simplify 1 (NCT01969838)
- Testing
- Momelotinib, Ruxolitinib
- Where
- 114 sites in United States, Australia and 20 more
- Volunteers
- 432 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability.
- Trial name
- NCT02226172
- Testing
- Glasdegib (PF-04449913)
- Where
- 19 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Polycythemia Vera, Thrombocythemia
Pomalidomide for Myelofibrosis Patients
The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.
- Trial name
- NCT00946270
- Testing
- CC-4047, Prednisone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis, Primary Myelofibrosis
Anti-TGF-beta Therapy in Patients With Myelofibrosis
TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-essential Thrombocythemia Related Myelofibrosis
- Trial name
- NCT01291784
- Testing
- monoclonal antibody to TGF-beta
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- John Mascarenhas
Primary Myelofibrosis, Post-Polycythemia Vera
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
- Trial name
- FREEDOM2 (NCT03952039)
- Testing
- FEDRATINIB, Best Available Therapy (BAT)
- Where
- 107 sites in Australia, Austria and 14 more
- Volunteers
- 202 people
- Sponsor
- Celgene
Myeloproliferative Disorders, Myelofibrosis
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus…
- Conditions
- Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
- Trial name
- INDEPENDENCE (NCT04717414)
- Testing
- ACE-536
- Where
- 185 sites in United States, Argentina and 24 more
- Volunteers
- 313 people
- Sponsor
- Celgene
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV)
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- Simplify 2 (NCT02101268)
- Testing
- Momelotinib, Best Available Therapy (BAT)
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis (MF)
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential…
- Trial name
- NCT02087059
- Testing
- Ruxolitinib
- Where
- 29 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01423851
- Testing
- NS-018
- Where
- 9 sites in United States
- Volunteers
- 77 people
- Sponsor
- NS Pharma, Inc.
Myelofibrosis, Polycythemia Vera
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocythemia
- Trial name
- NCT04629508
- Testing
- itacitinib
- Where
- 21 sites in United States, Austria and 5 more
- Volunteers
- 4 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis
Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
This was a study of treatment with ruxolitinib in patients who presented with transfusion dependent or independent anemia. Starting dose was 10 mg BID.
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- REALISE (NCT02966353)
- Testing
- ruxolitinib
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals